Calculate 10-year cardiovascular disease risk using the Framingham Risk Score. Evaluates age, sex, cholesterol, blood pressure, smoking, and diabetes.
The Framingham Risk Score (FRS) estimates the 10-year risk of developing cardiovascular disease using data from the landmark Framingham Heart Study, which has followed participants from Framingham, Massachusetts since 1948. The calculator incorporates age, sex, total cholesterol, HDL cholesterol, systolic blood pressure, antihypertensive medication use, smoking status, and diabetes to produce a probability estimate.
Risk categories guide statin therapy decisions and lifestyle intervention intensity: low risk (<5%) emphasizes lifestyle modification, borderline (5-9.9%) considers risk enhancers, intermediate (10-19.9%) benefits from moderate-intensity statin therapy if risk enhancers are present, and high risk (≥20%) warrants high-intensity statin therapy.
While the newer Pooled Cohort Equations (ASCVD calculator) are now preferred by AHA/ACC guidelines, the Framingham model remains widely used and provides validated risk estimation. This calculator also computes heart age, optimal risk comparison, and TC/HDL ratio for comprehensive cardiovascular assessment. Check the example with realistic values before reporting. Use the steps shown to verify rounding and units. Cross-check this output using a known reference case.
Cardiovascular disease remains the leading cause of death globally, responsible for approximately 18 million deaths annually. Risk prediction enables targeted preventive therapy — treating high-risk individuals with statins, antihypertensives, and aspirin (when appropriate) while avoiding unnecessary medication in low-risk populations.
The heart age concept (comparing actual risk to the risk of someone with optimal factors) is a powerful communication tool that motivates lifestyle change more effectively than abstract percentage risks.
Framingham Risk Score uses sex-specific Cox proportional hazards models: Male: S₁₀ = 1 − 0.88936^exp(ΣβᵢXᵢ − 23.9802) Female: S₁₀ = 1 − 0.95012^exp(ΣβᵢXᵢ − 26.1931) where βᵢ are regression coefficients for each risk factor and Xᵢ are log-transformed values.
Result: 12.5% — Intermediate Risk
A 55-year-old non-smoking, non-diabetic male with total cholesterol 220, HDL 50, and SBP 140 has an intermediate 10-year CVD risk. This risk would benefit from statin discussion especially if risk enhancers (family history, metabolic syndrome, elevated CRP) are present.
The 2018 AHA/ACC Cholesterol Guidelines establish four statin benefit groups: (1) Clinical ASCVD — high-intensity statin, (2) LDL ≥190 — high-intensity statin without risk calculation, (3) Diabetes age 40-75 — moderate-intensity statin, (4) 10-year risk ≥7.5% age 40-75 — discuss statin with risk enhancer assessment and optional CAC scoring.
Factors that favor statin therapy in the borderline/intermediate risk range: family history of premature ASCVD, persistently elevated LDL ≥160 mg/dL, metabolic syndrome, chronic kidney disease, chronic inflammatory conditions (RA, psoriasis, HIV), history of preeclampsia or premature menopause, South Asian ancestry, elevated hsCRP (≥2 mg/L), elevated Lp(a) (≥50 mg/dL or ≥125 nmol/L), elevated ApoB (≥130 mg/dL), or ankle-brachial index <0.9.
CAC scoring is the most powerful risk reclassifier available. CAC=0 is associated with very low event rates (<1% per decade) and can defer statin therapy in borderline/intermediate risk patients. CAC ≥100 or ≥75th percentile favors statin initiation. CAC is not recommended for low-risk (<5%) or high-risk (≥20%/known ASCVD) patients.
The Pooled Cohort Equations (2013) use data from multiple diverse cohorts (not just Framingham), include race as a variable, and predict atherosclerotic CVD events specifically. Framingham predicts broader CVD including heart failure and is validated over a longer period. The PCE are now preferred by ACC/AHA guidelines for statin decisions.
No. The 2018 ACC/AHA guidelines recommend shared decision-making for the 7.5-20% risk group. Risk enhancers (family history, LDL ≥160, metabolic syndrome, CKD, inflammatory conditions, high-risk ethnicity) favor statin initiation. Coronary artery calcium (CAC) scoring can reclassify risk: CAC=0 generally favors deferring statins.
The FRS tends to overestimate risk in low-risk populations (East Asian, Mediterranean). It may underestimate risk in South Asian, African American, and familial hypercholesterolemia populations. The ASCVD calculator partially addresses racial differences for Black and White Americans.
Heart age compares your actual risk to the risk that would be expected if all modifiable risk factors were at optimal levels. A 55-year-old with a heart age of 70 has the CVD risk of an average 70-year-old. This concept motivates lifestyle change more effectively than abstract probability.
Every 4-6 years for low-risk individuals, or whenever risk factors change significantly. After starting statin therapy, the calculator loses some validity because statins reduce both cholesterol levels and risk beyond what the lipid change alone would predict.
Total cholesterol and HDL are used because the TC/HDL ratio captures atherogenic risk better than any single lipid measure. LDL can be calculated from these values (Friedewald equation) and is used for treatment targets and monitoring, but TC and HDL proved more predictive in the original Framingham models.